Merck & Co., Inc., Rahway, N.J., USA Licenses KRAS G12D Drug, Books $400M Charge

Merck entered an exclusive global license with SciBrunch for preclinical KRAS G12D inhibitor SPR2015, paying $400M upfront, with total deal value up to $2.13B. Merck will record a pre-tax charge of $400M (~$0.13/share) in Q3 2026.Material DetailsContext by AI AnalystThis is an early-stage pipeline…